title: Immunopotentiation of live brucellosis vaccine by adjuvants.
abstract: In a series of studies in SPF and conventional guinea pigs, various adjuvants (larifan, polyoxidonium-PO, natrium thiosulphate-NT, TNF-β and Ribi adjuvant system-RAS) were evaluated for their ability to enhance immune responses to the live brucellosis vaccine, Brucella abortus strain 82-PS (penicillin-sensitive). Combining adjuvants with S82-PS increased synthesis of antibodies against rough (R) and smooth (S) Brucella antigens. Dynamics and levels of antibodies differed dependent upon the adjuvant. Adjuvants enhanced cell-mediated responses to S82-PS, and phagocytosis by macrophages. Humoral and cellular immune responses stimulated by the adjuvants correlated with increased vaccine protection against experimental challenge. The highest protection was demonstrated by combining TNF-β or PO with S82-PS. Our data demonstrates the potential of adjuvants to improve immunogenic properties of live brucellosis vaccines.
authors.affiliation: State Federal Enterprise for Science Research Centre for Toxicology and Hygienic Regulation of Biopreparations at Federal Medico-Biological Agency (RCT&HRB), Bld.102A, Lenin Str., Serpukhov, Moscow Region, Russia. toxic@online.stack.net
authors.forename: Alexander A
authors.initials: AA
authors.lastname: Denisov
authors.forename: Yulia S
authors.initials: YS
authors.lastname: Korobovtseva
authors.forename: Olga M
authors.initials: OM
authors.lastname: Karpova
authors.forename: Alla V
authors.initials: AV
authors.lastname: Tretyakova
authors.forename: Larisa V
authors.initials: LV
authors.lastname: Mikhina
authors.forename: Arkadyi V
authors.initials: AV
authors.lastname: Ivanov
authors.forename: Konstantin M
authors.initials: KM
authors.lastname: Salmakov
authors.forename: Roman V
authors.initials: RV
authors.lastname: Borovick
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D002004:Brucella Vaccine / Q000276:immunology*; D002003:Brucella abortus / Q000276:immunology*; D002006:Brucellosis / Q000276:immunology / Q000517:prevention & control*; D049109:Cell Proliferation; D017358:Cell Wall Skeleton / Q000276:immunology; D003311:Cord Factors / Q000276:immunology; D006168:Guinea Pigs; D007111:Immunity, Cellular; D056724:Immunity, Humoral; D008050:Lipid A / Q000031:analogs & derivatives / Q000276:immunology; D008233:Lymphotoxin-alpha / Q000276:immunology; D017737:Macrophages, Peritoneal / Q000276:immunology; D008297:Male; D009930:Organic Chemicals / Q000276:immunology; D010587:Phagocytosis; D010879:Piperazines / Q000276:immunology; D011108:Polymers
chemical_list: D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D002004:Brucella Vaccine; D017358:Cell Wall Skeleton; D003311:Cord Factors; D008050:Lipid A; D008233:Lymphotoxin-alpha; D009930:Organic Chemicals; D010879:Piperazines; D011108:Polymers; C075897:Ribi adjuvant; C066530:larifan; C540909:azoximer bromide